[go: up one dir, main page]

EA201792502A1 - Кабазитаксел и его применение для лечения рака - Google Patents

Кабазитаксел и его применение для лечения рака

Info

Publication number
EA201792502A1
EA201792502A1 EA201792502A EA201792502A EA201792502A1 EA 201792502 A1 EA201792502 A1 EA 201792502A1 EA 201792502 A EA201792502 A EA 201792502A EA 201792502 A EA201792502 A EA 201792502A EA 201792502 A1 EA201792502 A1 EA 201792502A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kabazitaxel
applications
cancer treatment
cancer
treatment
Prior art date
Application number
EA201792502A
Other languages
English (en)
Inventor
Мустафа Шаджаа
Жан-Франсуа Дедье
Сунил Гупта
Далила Селлами
Дороте Семион
Original Assignee
Авентис Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53177311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201792502(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Авентис Фарма С.А. filed Critical Авентис Фарма С.А.
Publication of EA201792502A1 publication Critical patent/EA201792502A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/30—Printed labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению, характеризующемуся следующей формулой (I), которое может находиться в форме основания или в форме гидрата или сольвата, для применения в качестве лекарственного препарата при лечении рака у пациентов с печеночной недостаточностью.
EA201792502A 2015-05-13 2016-05-12 Кабазитаксел и его применение для лечения рака EA201792502A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305720.3A EP3093014A1 (en) 2015-05-13 2015-05-13 Cabazitaxel and its use for treating cancer
PCT/EP2016/060759 WO2016180943A1 (en) 2015-05-13 2016-05-12 Cabazitaxel and its use for treating cancer

Publications (1)

Publication Number Publication Date
EA201792502A1 true EA201792502A1 (ru) 2018-02-28

Family

ID=53177311

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792502A EA201792502A1 (ru) 2015-05-13 2016-05-12 Кабазитаксел и его применение для лечения рака

Country Status (15)

Country Link
US (1) US20160331717A1 (ru)
EP (3) EP3093014A1 (ru)
JP (1) JP2018516890A (ru)
KR (1) KR20180006417A (ru)
CN (1) CN108135878A (ru)
AU (1) AU2016259775A1 (ru)
CA (1) CA2985408A1 (ru)
EA (1) EA201792502A1 (ru)
ES (1) ES2774101T3 (ru)
IL (1) IL255541A (ru)
MX (1) MX2017014463A (ru)
PL (1) PL3294285T3 (ru)
PT (1) PT3294285T (ru)
TW (1) TW201705950A (ru)
WO (1) WO2016180943A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
ES2248684T3 (es) 2003-07-02 2006-03-16 Scheuten Glasgroep Procedimiento para la fabricacion de un acristalamiento contra incendios.
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
ES2862340T3 (es) 2009-10-29 2021-10-07 Sanofi Mature Ip Nuevo uso antitumoral de cabazitaxel
BR112012012210B8 (pt) * 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
CN103826634A (zh) * 2011-09-15 2014-05-28 诺华股份有限公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer

Also Published As

Publication number Publication date
TW201705950A (zh) 2017-02-16
IL255541A (en) 2018-01-31
AU2016259775A1 (en) 2018-01-04
CA2985408A1 (en) 2016-11-17
EP3093014A1 (en) 2016-11-16
US20160331717A1 (en) 2016-11-17
PT3294285T (pt) 2020-03-06
KR20180006417A (ko) 2018-01-17
EP3294285A1 (en) 2018-03-21
JP2018516890A (ja) 2018-06-28
EP3294285B1 (en) 2019-12-18
ES2774101T3 (es) 2020-07-16
CN108135878A (zh) 2018-06-08
WO2016180943A1 (en) 2016-11-17
PL3294285T3 (pl) 2020-05-18
MX2017014463A (es) 2018-03-21
EP3643307A1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
PH12017500207B1 (en) Indoles for use in influenza virus infection
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
EA201591340A1 (ru) Модулятор андрогенного рецептора и его применения
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201591624A1 (ru) Новые производные пиразола
CL2015002897A1 (es) Inhibidores de bace1
GEP201706725B (en) Compounds and compositions as inhibitors of mek
EA201791174A1 (ru) Антимикотическое соединение
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
PH12018501709A1 (en) Naphthridinedione derivatives